CCL8, also known as MCF2, acts as an agonist of the CC chemokine receptor type 2 (CCR2) and CCR5, exerting significant function in the process of leukocyte chemotaxis, cancer tumorigenesis and progression, and responds to changes in the pathogenic environment [35,36]. This evidence concerns the gene CCR5 and cancer.